Try our Advanced Search for more refined results

Expert Analysis

2 Anti-Kickback Developments Hold Lessons For Biopharma

By Mary Kohler ( February 13, 2025, 6:25 PM EST) -- Last year ushered in new Anti-Kickback Statute concerns for biopharma companies after Ultragenyx Pharmaceutical Inc. paid $6 million to settle U.S. Department of Justice allegations about its free genetic testing program in late 2023.[1] As the industry asked why, prosecutors warned of more to come.[2] At year-end, they delivered....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!